NASDAQ: GPCR - Structure Therapeutics Inc.

Yield per half year: -25.02%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Structure Therapeutics Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

more details
The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2023-02-03
ISIN US86366E1064
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://structuretx.com
Цена ао 41.15
Change price per day: -1.69% (29.54)
Change price per week: +4.09% (27.9)
Change price per month: -13.96% (33.75)
Change price per 3 month: -30.44% (41.75)
Change price per half year: -25.02% (38.73)
Change price per year: -28.75% (40.76)
Change price per 3 year: 0% (29.04)
Change price per 5 year: 0% (29.04)
Change price per 10 year: 0% (29.04)
Change price per year to date: -21.45% (36.97)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 2.88 6
P/E 0 0
EV/EBITDA -11.6 0
Total: 2.75

Efficiency

Title Value Grade
ROA, % -18.58 0
ROE, % -19.77 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0536 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 642243.75 10
Yield EPS, % 384724.96 10
Total: 8
More

Institutions Volume Share, %
Wellington Management Group, LLP 4372326 9.38
FMR, LLC 4034584 8.66
Driehaus Capital Management, LLC 2599079 5.58
Avoro Capital Advisors LLC 2333333 5.01
Federated Hermes, Inc. 2267206 4.87
Tcg Crossover Management, Llc 2109584 4.53
Adage Capital Partners GP L.L.C. 1756918 3.77
Price (T.Rowe) Associates Inc 1679436 3.6
Janus Henderson Group PLC 1544416 3.31
T. Rowe Price Investment Management, Inc. 1312195 2.82

ETF Share, % Profitability for 1 year, % Dividends, %
Future Tech ETF 0.24233 426.34 0.8416
Principal Healthcare Innovators ETF 0.24233 618.5 0.8416



Head Job title Payment Year of birth
Dr. Raymond C. Stevens Ph.D. CEO & Director 890.38k 1964 (61 year)
Dr. Yingli Ma Ph.D. Chief Technology Officer 497.58k 1974 (51 year)
Mr. Jun S. Yoon Co- Founder, CFO & Secretary 627.64k 1978 (47 years)
Dr. Xichen Lin Ph.D. Chief Scientific Officer N/A 1974 (51 year)
Mr. Tony Peng Senior Vice President of Legal N/A
Mr. Bob Gatmaitan Senior Vice President of People N/A
Dr. Hui Lei Ph.D. Senior Vice President of Chemistry N/A
Dr. Fang Zhang Ph.D. Executive VP & Head of Biology N/A
Ms. Lani Ibarra Senior Vice President of Clinical Development Operations N/A
Dr. Xinglong Jiang Ph.D. Senior Vice President of Preclinical Development

Address: United States, South San Francisco. CA, 611 Gateway Boulevard - open in Google maps, open in Yandex maps
Website: https://structuretx.com